Javara

Javara's business model is centered around Clinical Research as a Care Option (CRAACO). This means that they integrate clinical research into the patient's healthcare journey, connecting them with relevant clinical trials at the right time. This approach helps to overcome the inefficiencies that often cause delays in clinical trials, such as lack of patient participation or slow data collection.

Javara's services are particularly valuable to biopharma, biotech, and Contract Research Organizations (CROs), who benefit from the robust and reliable data generated through Javara's integrated approach. This data not only expedites the FDA approval process but also contributes to reducing the overall drug development time cycle.

The company's mission is to bridge the gap between clinical research and clinical care, addressing the inequities in the current system and driving change through innovative solutions. By diversifying clinical research, Javara aims to provide more patients with access to potentially life-changing care options.

In terms of revenue, Javara likely makes money by charging healthcare organizations for their services and possibly also receives fees from the biopharma, biotech, and CRO companies that benefit from the data they generate.